Dibutyl phosphate

Dibutyl phosphate (DBUP) is a urinary metabolite of organophosphate esters (OPEs) . Dibutyl phosphate is positively correlated with an increased risk of sarcopenia[1][2][3].

Product Specifications

CAS Number

[107-66-4]

Product Name Alternative

DBUP

UNSPSC

12352211

Hazard Statement

H314, H351

Target

Drug Metabolite

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Purity

97.0

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O=P(OCCCC)(O)OCCCC

Molecular Formula

C8H19O4P

Molecular Weight

210.21

Precautions

H314, H351

References & Citations

[1]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64 (2) :226-35.|[2]Villhauer EB, et al. 1-[[ (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S) -pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46 (13) :2774-89.|[3]Nan W, Peng Z, Yi T, Ouyang M, Hu J. Association between exposure to organophosphate esters metabolites and sarcopenia prevalence: A cross-sectional study using NHANES data. Ecotoxicol Environ Saf. 2024 Oct 15;285:117041.